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Abstract
Background: Thyroid hormone replacement is one of the most commonly prescribed and cost
effective treatments for a chronic disease. There have been recent changes in community
prescribing policies in many areas of the UK that have changed patient access to necessary
medications. This study aimed to provide a picture of thyroid hormone usage in the UK and to
survey patient opinion about current community prescribing policies for levothyroxine.
Methods: Data on community prescriptions for thyroid hormones in England between 1998 and
2007, provided by the Department of Health, were collated and analysed. A survey of UK members
of a patient support organisation (the British Thyroid Foundation) who were taking levothyroxine
was carried out.
Results: The amount of prescribed thyroid hormones used in England has more than doubled,
from 7 to almost 19 million prescriptions, over the last 10 years. The duration of prescriptions has
reduced from 60 to 45 days, on average over the same time. Two thousand five hundred and fifty
one responses to the patient survey were received. Thirty eight percent of levothyroxine users
reported receiving prescriptions of 28 days' duration. 59% of respondents reported being
dissatisfied with 28-day prescribing.
Conclusion: Amongst users of levothyroxine, there is widespread patient dissatisfaction with 28-
day prescription duration. Analysis of the full costs of 28-day dispensing balanced against the
potential savings of reduced wastage of thyroid medications, suggests that this is unlikely to be an
economically effective public health policy.
Background
Since 1968, most forms of hormone replacement therapy,
including levothyroxine, have been dispensed free of
charge to NHS patients in England and Wales, under the
medical exemption scheme. Thus, patients taking essen-
tial medications have been able to access a continuous
supply, irrespective of their means. Patients with both
autoimmune and congenital hypothyroidism require thy-
roid hormone replacement, in addition to those who have
had surgical thyroidectomy or ablative radioiodine treat-
ment for hyperthyroidism and thyroid cancer. Since
hypothyroidism from all these causes is a chronic and irre-
versible condition, the majority of hypothyroid patients
will require lifelong thyroid hormone treatment. About
19 million prescriptions for thyroid hormone prepara-
tions were dispensed in England during 2007, making it
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one of the most frequently prescribed medications[1].
From the above data, one can estimate that slightly over
3% of the population of England were prescribed regular
levothyroxine during 2007[2]. This is corroborated by a
prevalence rate for hypothyroidism of 3.01% in Tayside,
Scotland during 2001[3].
Hypothyroidism as a clinical syndrome was first recog-
nised in the 1870s and its subsequent treatment with
extract of animal thyroid was first achieved in Newcastle
upon Tyne during the 1890s by Murray[4]. Synthetic thy-
roid hormone replacement therapy has been available
since 1927, when British chemists Harington and Barger
first synthesised thyroxine[5]. So, for more than 50 years,
thyroid hormone replacement has predominantly been
formulated as synthetic levothyroxine (T4). Nevertheless,
in recent years there has been a minor trend away from
levothyroxine monotherapy in the treatment of hypothy-
roidism. This has taken two distinct forms: use of tri-
iodothyronine (liothyronine, T3) either as monotherapy,
or more commonly combined with levothyroxine (T3/
T4); and use of desiccated porcine thyroid (marketed as
Armour 'Natural' thyroid). The use of combined T3/T4
was re-explored following a small but high profile study
of thyroid cancer patients who were swapped from sup-
pressive levothyroxine therapy, to a lesser dose of com-
bined T3/T4[6]. Subsequent to this study, a further 10
larger studies, involving, in total, more than 1000 patients
largely with autoimmune hypothyroidism, have failed to
reproduce a benefit from combined T3/T4[7]. Neverthe-
less, there is no current formulation of T3/T4 that repli-
cates the natural pattern and relative quantities of these
hormones released from the human thyroid, and a slow
release preparation might have utility in the future. The
movement towards use of porcine thyroid extract in the
UK has been largely patient-led, with the support of a few
fringe practitioners, with many patients believing there
could be some additional benefit from use of a 'natural'
preparation compared to use of synthetic hormones. As
there has never been a randomised trial of levothyroxine
versus porcine thyroid extract, any possible health benefit
remains uncharacterised, although most conventional
practitioners have been cautious to recommend such ther-
apy, as porcine thyroid is known to synthesise substan-
tially more T3 than human thyroid[8]. In addition,
porcine thyroid extract is substantially more expensive
than the 4 pence for a 100 microgram levothyroxine tab-
let.
As concerns grow over increasing healthcare costs, local
primary care organisations (PCOs) have developed strate-
gies aimed at rationalising resource use and providing
good value in health care spending. Prescription drug
wastage and over-prescribing have been identified as par-
ticular targets for this economy drive, and over the last 5
years many PCOs have implemented new initiatives to
reduce drug costs. One such strategy has been for PCOs to
recommend that GPs prescribe only a 28-day supply of
medication at one time. This 28-day prescribing policy
followed several studies which demonstrated that
restricted and closely monitored prescribing periods
reduced over-prescribing and medicine wastage[9-11].
One scheme introduced in Kirklees estimated that by
doing this, drug wastage would be reduced by approxi-
mately 33%[11]. Nevertheless, most PCOs have recog-
nised that for certain medications, most notably oral
contraceptives, the detrimental effect of an interrupted
patient supply would not be acceptable, and therefore
exempted these from the policy. In a similar way, several
PCOs have seen that for inexpensive and long-term med-
ications (eg. oestrogen hormone replacement), there are
few savings to be made and have exempted these from the
28-day prescribing policy. However, many practices in the
UK have applied the 28-day prescription recommenda-
tion indiscriminately and without flexibility, and this may
have had an untoward effect on numerous patients taking
long-term medications, including levothyroxine. The
impact of this prescribing policy on, and its acceptability
with, patients taking regular medications has never been
evaluated. In this paper, we document the trends in pre-
scription of thyroid hormones in England over the last 10
years. We also provide the first information on the imple-
mentation of the 28-day prescribing recommendation
across the UK with relation to levothyroxine, including
patient perceptions and satisfaction with the policy.
Methods
Trends in thyroid hormone prescribing; England 1998–
2007
Trends in prescription drug usage were monitored by ana-
lysing annual data published by the Department of
Health (DoH), known as Prescription Cost Analysis
(PCA) statistics. The PCA provides details of the number
of items and the net ingredient cost of the prescriptions
dispensed from community pharmacies in England.
These data are based on information obtained from pre-
scriptions sent to the Prescription Pricing Division for
payment and include all prescriptions dispensed in the
community. This includes prescriptions dispensed by
pharmacists, appliance contractors, dentists, general prac-
titioners, prescriptions from hospital doctors dispensed in
the community and items personally administered by
doctors. We analysed the PCA data for England only,
which are released on a yearly basis, from April 1998 to
2007, inclusive. By analysing PCA data, it is possible to
ascertain the trends in thyroid hormone usage on a year
by year basis and therefore the cost of thyroid hormone
usage to the NHS. Data extracted included the number of
thyroid hormone prescriptions dispensed in England per
year, the cost of these prescription items and data to allowBMC Public Health 2009, 9:132 http://www.biomedcentral.com/1471-2458/9/132
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the calculation of the approximate prescription length
administered (quantity of tablets per prescription). Infor-
mation about dispensing tariffs was obtained from the
prescription pricing division of the NHS business services
agency.
Questionnaire survey of British Thyroid Foundation (BTF) 
membership 2007
To explore the perceptions of the 28-day prescribing rec-
ommendation amongst patients receiving thyroid hor-
mone replacement treatment, a questionnaire was
designed by the authors and reviewed by a patient mem-
bers panel of the British Thyroid Foundation (BTF). This
was distributed by the BTF with their quarterly newsletter
in August 2007. The BTF is a registered charity that works
with medical professionals to provide information and
support to people with thyroid disorders. The quarterly
newsletter was distributed to 6121 members of the BTF, of
whom 6083 were UK residents. The survey aimed to
explore how long respondents had been taking thyroid
replacement treatment, how they obtained their prescrip-
tions, and their concerns, comments and experiences
about 28-day prescribing. The full questionnaire is availa-
ble on request from the authors (see additional file 1).
Ethics committee approval was not needed for this study
as it was instigated at the request of BTF representatives
and not performed on any NHS site. Permission to use
anonymous data for the purposes of publication was
granted by the Trustees of the BTF.
Results
Thyroid hormone usage in England
Since 1998, thyroid hormone usage, and therefore the
cost that these prescriptions incur, has increased dramati-
cally. The number of prescription items dispensed in Eng-
land for all forms of thyroid hormone replacement has
more than doubled from just over 7 million in 1998 to
close to 19 million in 2007 (figure 1, panel A). Levothy-
roxine (T4) is the most commonly prescribed thyroid hor-
mone, representing over 99.7% of all thyroid hormone
prescriptions. Liothyronine (tri-iodothyronine, T3) and
Armour thyroid make up the rest of thyroid hormone pre-
scriptions, totalling 0.30 and 0.008%, respectively in
2007. Figure 1, panel B illustrates the total yearly cost of
thyroid hormone replacement therapy prescriptions.
The PCA data also reveal a change in the content of pre-
scriptions over the 10-year period of observation (figure 2,
panel A). During 1998, there were just over 2.8 million
prescriptions for thyroxine 100 μg tablets in England and
the mean content of each prescription was 59.7 tablets.
This is sufficiently close to the figure of 56 tablets to
assume that the mode prescription length was likely to be
56-days or 8 weeks. By 2007, there were 7.0 million pre-
scriptions for levothyroxine 100 μg tablets and the mean
content of each prescription was reduced to 44.9 days,
slightly over 6 weeks.
British Thyroid Foundation member survey
Two thousand, five hundred and fifty one individuals tak-
ing levothyroxine responded to the questionnaire (42% of
those dispatched to UK residents), which enquired about
patient experiences of obtaining levothyroxine and
sought opinions about restricted prescription lengths.
Ninety six percent of respondents had been taking lev-
othyroxine tablets for more than a year, with more than
70% of people taking them for more than 5 years. With
regard to length of prescription available, 38% of
respondents were being prescribed levothyroxine for 28
days at a time, with only 28% receiving prescriptions for 3
months (84 days); figure 2, panel B.
The majority of respondents describe being unhappy with
the 28-day prescribing arrangement, 59% of people being
dissatisfied overall, compared to just 13% feeling satisfied
(figure 3, panel A). However, fewer than half of people
who were prescribed levothyroxine for 28 days had asked
their primary care practitioners for a longer prescription.
Of those who had asked, it appears that approximately
half of practitioners had agreed to prescribe a longer
amount, with the other half declining to extend the pre-
scription when asked. Seventeen percent of people
responding to the survey admitted to having missed lev-
othyroxine tablets, with 6% having gone without tablets
on more than one occasion, owing to a lack of dispensed
medication.
When asked what the major reasons for dissatisfaction
with the 28-day prescribing policy were, the two most
common responses were that it is simply inconvenient to
pick up the prescription/tablets more frequently or that it
interferes with the working day (figure 3, panel B). In free
text comments several other common themes emerged:
• In rural areas people have to travel significant dis-
tances to get their prescription, sometimes making
more than one journey per prescription (e.g. to order
it, pick it up and have it dispensed).
￿ Those with physical disabilities described problems
getting to the practice.
￿ Many people feel that asking for a repeat prescrip-
tion is a waste of their doctor's time and that they
don't want to bother the doctor for something so sim-
ple.
￿ Working long hours or shift-work make it difficult
for many people to get to the surgery or pharmacy dur-
ing limited opening times.BMC Public Health 2009, 9:132 http://www.biomedcentral.com/1471-2458/9/132
Page 4 of 9
(page number not for citation purposes)
Quantity and cost of thyroid hormone replacement in England Figure 1
Quantity and cost of thyroid hormone replacement in England. Panel A – The number of prescription items dis-
pensed in thousands for all thyroid hormone replacement therapies (levothyroxine, liothyronine and Armour thyroid) from 
1998 to 2007 (PCA data). Panel B – Net ingredient cost of thyroid hormone replacement therapy in England from 1998 to 
2007.
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Length of levothyroxine prescriptions Figure 2
Length of levothyroxine prescriptions. Panel A – Temporal trend in the mean prescription content, for levothyroxine 
100 μg tablets, from 1998 to 2007 in England (PCA data). Panel B – Length of prescription issued to patients responding to 
BTF survey (n = 2551 responses).
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Patient opinion about 28-day prescribing Figure 3
Patient opinion about 28-day prescribing. Data taken from BTF survey responses. Panel A – Patient satisfaction with the 
28 day prescribing policy. Panel B – Most frequent responses of reasons for dissatisfaction with the 28 day prescribing.
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￿ Some people leave the UK on holiday for more than
a month each year, and this also causes a problem.
￿ In contrast, when other medications are being pre-
scribed every 28 days, several people comment that it
makes it easy to remember that all the prescriptions
are for 28 days, and that they have to go back for their
other medications anyway.
Analysis of non-drug costs
Levothyroxine is a remarkably cheap drug, costing about
£1.12 for a 28-day supply of 100 μg tablets; the total
yearly cost for the drug itself being around £14.50 per
patient at this dose. Thus, the professional fee for the
pharmacist of £0.90 per item dispensed makes up a signif-
icant cost in the delivery of the treatment to the patient.
These figures allow one to calculate that to treat a patient
for a year with levothyroxine dispensed every 84 days
costs around £18.40, whereas the professional fees to dis-
pense the drug an additional 9 times during the course of
a year of treatment, as required with a 28-day supply,
incurs a total cost of £26.30. This estimate does not factor
in additional costs incurred, such as practice receptionist
or doctor time to print out, check and sign the additional
prescriptions. Thus, 28-day prescribing of levothyroxine is
substantially more expensive to the NHS than giving
longer supplies. The increased costs of restricted prescrip-
tion lengths is supported by work carried out in America
which calculated that the cost of a variety of drug therapies
actually increases with a shorter prescription length, 34
days, compared to a longer prescription of 100 days[12].
Discussion
Analysis of the PCA data clearly shows an increase in the
prescribing of thyroid hormone treatments from 1998 to
2007. There may be a number of possible explanations for
this trend. Firstly, hypothyroidism becomes more preva-
lent with advanced age. It is likely that as longevity
increases, increasing numbers of elderly people will
require continued thyroid hormone replacement.
Another contributory factor may be an increase in thyroid
function testing by GPs. This may result in more patients
with hypothyroidism being identified, or, perhaps more
likely, earlier detection and treatment of individuals with
subclinical hypothyroidism who may not previously have
been identified or, had they been identified, started on
treatment. With the recognition that radioiodine is a safe,
acceptable and highly cost-effective treatment for women
of childbearing age with thyrotoxicosis[13], it is possible
that more patients with hyperthyroidism are rendered
hypothyroid following radioiodine ablation at an earlier
stage of their treatment. A final possibility is that public
perceptions of health have shifted slightly, such that
health is perceived as being more than simply the absence
of disease, leading more people to aspire towards a posi-
tive sense of wellbeing. With this objective, more individ-
uals are seeking "check ups" that include thyroid function
testing in 'well person' clinics. Such people may then be
found to have mild or subclinical hypothyroidism and be
commenced on thyroid hormone treatment. Thus, it
seems likely that a combination of the above factors has
led to the dramatic rise in thyroid hormone usage.
The cost of thyroid hormone treatment to the NHS has
also been increasing, in keeping with the trend of
increased prescribing of thyroid hormone treatment. Even
so, thyroid hormone treatment remains inexpensive com-
pared with many drugs available, with 100 μg of levothy-
roxine costing just less than 4 pence.
Drug wastage seems to occur because many medical prob-
lems improve and subsequently resolve, at which point
the patient then stops taking the medication. If a three-
month prescription is issued in this instance, far more
medication is wasted than if a one-month prescription is
issued. Another reason for wastage of prescription drugs is
that a person may stop taking them due to unwanted side
effects, which are likely to occur soon after the drug is
started. Restricting prescriptions to 28 days has been pro-
posed to reduce drug wastage. The reported benefits[14]
of the 28-day prescribing policy include:
1) Reducing confusion in patients by limiting the
number of medication packets that they will have at
home at any time.
2) Allowing medication to be made into a 28-day
"blister pack" or dosing cassette making it easier for
patients to remember to take their medications.
3) Having a fixed prescription period allows all the
medications for a single patient to be dispensed and
therefore renewed at the same time, thus reducing the
number of prescriptions a practice has to process.
4) Having a fixed prescription period makes it easier
for health care professionals to identify appropriate
times for patients to have a review of their medication.
5) Having a fixed prescription period allows patients
to have regular contact with a primary healthcare pro-
fessional (doctor, nurse or pharmacist) so that any
problems with their medications can be discussed and
rectified.
6) A fixed prescription period would allow concord-
ance issues to be more readily identified, as patients
ordering prescriptions early or late can be easily iden-
tified.BMC Public Health 2009, 9:132 http://www.biomedcentral.com/1471-2458/9/132
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Although the 28-day prescribing policy has some benefits
in principle, in practice the policy has some clear disad-
vantages for certain groups of patients. This is particularly
so for individuals taking inexpensive medication, lifelong.
The analysis of the non-drug costs associated with lev-
othyroxine usage (i.e. pharmacist's professional fees for
dispensing, doctor and practice staff time) show that there
is little hope of recouping cost for any wasted drug using
a 28-day prescribing approach. We previously estimated
that the extra professional dispensing fees for levothyrox-
ine prescriptions alone would add at least £7 m of treat-
ment costs annually in England[15].
Although the responses to the survey distributed to BTF
members clearly represent only a proportion of national
opinion, of those patients that responded, more than one
third were currently being given 28-day levothyroxine pre-
scriptions, and the majority of respondents were dissatis-
fied with this. There are several good reasons why this
should be so (see free text comments above). In addition,
more than one in six patients report having gone without
their prescription medication due to difficulty in obtain-
ing it. Furthermore, patients taking levothyroxine whose
thyroid status is fluctuating or whose dose needs adjusting
are generally recommended to alter the dose and have a
repeat blood test in 8 to 12 weeks[2]. So the arbitrary
nature of the 28-day recommendation makes little sense
in terms of clinical practice either.
The PCA dispensing data was collected by the Prescription
Pricing Division in a standardised way during the period
of study, so we believe this data to be reliable. The British
Thyroid Foundation survey was sent to 6083 UK mem-
bers, although not all of them would have been levothy-
roxine users. While we do not know the exact response
rate in people being prescribed levothyroxine, it is clearly
a possibility that we have obtained the views only of the
most disgruntled members; patients with no issues being
less likely to respond. Thus, our analysis could be unrep-
resentative of the general opinion of levothyroxine users.
Despite these possible limitations, there is no other pub-
lished information of this nature available, and even if
considered at a qualitative level only, the survey findings
do provide an authentic insight into the patient experi-
ence.
Conclusion
The data we present illustrate that a fuller and more con-
sidered analysis of 28-day prescribing recommendations
should be carried out. Importantly, the likely impact of
restricted prescribing duration on patients, balanced
against the likelihood of cost saving, should be evaluated
on a drug-by-drug basis. We feel that an indiscriminately
applied 28-day prescribing policy is clearly inappropriate
for cheap medications and for those medications that
have to be taken lifelong. Our analysis may be equally
applicable to several other categories of medications
including those for other endocrine conditions (e.g.
hydrocortisone[16]) and for the treatment of several other
chronic conditions.
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